Functional neuroimaging identifies a cross-species biomarker for treatment monitoring in Angelman syndrome

Imagine the brain as a bustling city where billions of tiny messengers (neurons) are constantly sending signals to keep everything running. Sometimes, the city's power grid gets a bit glitchy. In a condition called Angelman syndrome, a specific "instruction manual" for the brain's power management is missing. This leads to a city that is a bit too loud, with signals firing off in chaotic bursts, causing severe developmental delays, movement issues, and a lack of speech. For a long time, doctors have been trying to find a reliable way to measure how "glitchy" this city is, especially to see if new medicines are fixing the problem. The usual way to listen to the city's hum is with an EEG, which uses sticky electrodes on the scalp to catch electrical sparks. But for many people with Angelman syndrome, sitting still long enough for those electrodes to work is incredibly difficult, and the electrical noise changes as they get older, making it hard to track progress over time. Scientists needed a new way to "see" the brain's activity that was gentle, easy to use, and worked the same way whether the subject was a mouse or a human.

This is where a team of researchers stepped in with a clever idea: instead of listening to the electricity, let's watch the blood flow. Think of the brain like a busy restaurant; when the chefs (neurons) start cooking up a storm, they need more fuel, so the waiters rush more blood to the kitchen. By measuring this rush of blood, scientists can tell how hard the brain is working. In this study, the team used two different "cameras" to watch this blood flow. First, they looked at mice with Angelman syndrome using a special light-based camera that can see tiny changes in blood color on the surface of the brain. Then, they took a similar, portable camera called fNIRS (functional near-infrared spectroscopy) and used it on real people with Angelman syndrome. The goal was to see if the "blood rush" looked the same in both the mice and the humans, and if fixing the missing instruction manual in the mice would calm down that rush.

The researchers found that the brain's blood flow in Angelman syndrome is like a fire alarm that is stuck on "high volume." In both the mice and the people, when they looked at a visual stimulus (like a flashing pattern), their brains sent a much bigger and more chaotic wave of blood than usual. It wasn't just a little louder; it was a distinct, amplified signal that stayed the same whether the subject was a young mouse, an adult mouse, a child, or an adult human. This "super-rush" of blood was so consistent that the team could use it to tell the difference between a healthy brain and an Angelman brain with very high accuracy, even better than looking at behavior alone.

But the most exciting part was what happened when they tried to fix the problem. In the mice, the scientists used two different treatments to restore the missing instruction manual. One treatment was like a gene delivery truck that dropped off the missing parts, and the other was a molecular "eraser" that removed the blockage preventing the brain from making its own parts. When they did this, the "super-rush" of blood in the mice's brains didn't just get a little quieter; it went back to normal levels. The more the brain's instruction manual was restored, the more the blood flow calmed down, and the better the mice moved around. This proved that this blood-flow signal is not just a random symptom; it is a direct reflection of the disease and a sensitive gauge for how well a treatment is working.

When they turned their attention to humans, they faced a tough challenge: people with Angelman syndrome often move a lot, which usually ruins brain scans. However, the team developed a special way to clean up the data, and it worked. They found that the people with Angelman syndrome showed the exact same "super-rush" pattern as the mice. Even though the people were different ages and had different types of the condition, the amplified blood flow remained a stable feature. This suggests that this blood-flow measure is a reliable "cross-species" biomarker. It means that scientists can test a new drug in mice, see if the blood flow calms down, and be confident that the same measurement will work in humans to see if the drug is helping.

In short, this paper suggests that watching the brain's blood flow is a powerful new tool. It acts like a universal translator, speaking the same language in mice and humans. It shows that the brain in Angelman syndrome is in a state of hyper-excitability that can be measured, and more importantly, it can be used to track whether treatments are successfully fixing the root cause of the problem. While the study doesn't claim to have cured Angelman syndrome, it provides a very promising, non-invasive way to monitor if future therapies are actually working, potentially speeding up the journey to effective treatments.